Verona Pharma PLC Director Dealing (6095M)
January 21 2016 - 7:24AM
UK Regulatory
TIDMVRP
RNS Number : 6095M
Verona Pharma PLC
21 January 2016
Verona Pharma plc
("Verona Pharma" or the "Company")
Director Dealing
21 January 2016, Cardiff - Verona Pharma plc (AIM: VRP) received
notification that on 20 January 2016 David Ebsworth, Director of
the Company, purchased 400,000 ordinary shares of 0.1 pence each of
the Company ("Ordinary Shares") at a price of 2.5 pence per
Ordinary Share.
Following the transaction David Ebsworth has a total interest of
4,599,774 Ordinary Shares, representing 0.46% of the total voting
rights.
-Ends-
For further information please contact:
Verona Pharma plc Tel: +44 (0) 20 3283
4200
Jan-Anders Karlsson, Chief
Executive Officer
N+1 Singer Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer
FTI Consulting Tel: +44 (0)20 3727 1000
Simon Conway / Stephanie
Cuthbert / Natalie Garland-Collins
Notes to Editors
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biopharmaceutical
company focused on the development of innovative prescription
medicines to treat respiratory diseases with significant unmet
medical needs, such as chronic obstructive pulmonary disease
(COPD), asthma and cystic fibrosis.
Verona Pharma's lead drug, RPL554, is a first-in-class drug
currently in Phase II trials as a nebulised treatment for acute
exacerbations of COPD in the hospital setting. The drug is a dual
phosphodiesterase (PDE) 3/4 inhibitor and therefore has both
bronchodilator and anti-inflammatory effects, which are essential
to the improvement of patients with COPD and asthma.
Verona Pharma is also building a broader portfolio of
RPL554-containing products to maximise its benefit to patients and
its value. This includes the very significant markets for COPD and
asthma maintenance therapy. The Company is also exploring the
potential of the drug in different diseases, such as cystic
fibrosis, where it is in pre-clinical testing and has received a
Venture and Innovation Award from the Cystic Fibrosis Trust.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSSEDFEFFMSEEF
(END) Dow Jones Newswires
January 21, 2016 07:24 ET (12:24 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024